The topic of this article may not meet Wikipedia's general notability guideline. (February 2024) |
This article needs additional citations for verification. (February 2024) |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.[1][2]
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Company type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
Key people | Kung-Yee Liang (Chairman) |
| Website | www.obipharma.com |
This section needs expansion. You can help by adding to it. (February 2020) |
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).[3]
History edit
The company was founded by Micheal N.Chang on April 29, 2002.[4] It was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
Primary Focus edit
The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.[5]
References edit
- ^ "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
- ^ "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
- ^ "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
- ^ "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
- ^ "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.